Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Human Albumin Industry Report 2014" report ... Albumin Industry Report 2014 is a professional and in-depth ... albumin industry. The report provides a basic ... industry chain structure. The human albumin market analysis is ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
(Date:9/18/2014)... Woburn, MA (PRWEB) September 18, 2014 ... Single Molecule Sequencing (tSMS™) technology, announced today the ... round of investment, led by Genomic Diagnostic Technologies, ... scientific and diagnostic applications. , Founded in March ... Scientist and Bioinformatics Analyst at Helicos BioSciences, SeqLL ...
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Using solar energy to turn raw materials into ingredients for every day life 2
... their voracious appetite for wood, rendering houses to dust and ... provide the biochemical means to a greener biofuel future. ... mine of microbes that have now been tapped as a ... or waste biomass to valuable biofuels. , The ...
... will utilise technologies not currently available. An example of ... as interconnects for computer chips. This is now a ... nanotechnology researchers within the Materials Ireland Polymer Research Centre ... develop such junction structure nanotubes used various different methods ...
... us, in us and for us. Imagine them seeking out ... place. Just as a car is a combination of a ... etc, nanomachines too need to be constructed from a range ... of actuator to open and close things, to absorb shock, ...
Cached Biology Technology:DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 2DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 3DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 4DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 5Understanding of actuator properties of carbon nanotubes bring micro machines closer 2
(Date:9/17/2014)... environmental impact recently scored a major win. In August, ... bags, and Governor Jerry Brown is expected to sign ... without a fight, according to an article in ... the American Chemical Society. , Alexander Tullo, a senior ... its first small victory in 1990 when Nantucket became ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2
... Detroit automaker, it appears that nature prefers to build its ... combining advanced computational modeling and cutting-edge experiments by molecular biologists ... the most stable parts of a protein are also the ... Sept. 13 issue of the journal Structure. , Nature refuses ...
... are miniature labs that can be swallowed like a ... Their function is to screen for, detect, and ... still at a single-cell size in early development stages. ... and water. , Engineering researchers at McMaster University will ...
... the event of a large-scale smallpox bioterrorist attack in ... researchers at Fred Hutchinson Cancer Research Center that appears ... Instead, the current U.S. government policy of post-release surveillance, ... and close contacts would be sufficient to thwart an ...
Cached Biology News:Protein folding: Building a strong foundation 2Nano-devices hold promise for early-stage cancer detection 2Nano-devices hold promise for early-stage cancer detection 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 4Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 5
Human PDGF, CF...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... The mycobacteria in Complete Freund's adjuvant ... injection site which enhances the immuneresponse. For ... used for the initial injections; Incomplete Freund's ... Antigens (preferably in saline) are typically mixed ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: